{"disease":{"id":"hyperoxaluria","name":"hyperoxaluria"},"drugs":{"marketed":[{"drug_id":"lumasiran","indication_name":"Primary hyperoxaluria, type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxlumo","generic_name":"LUMASIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"Hydroxyacid oxidase 1 (HAO1) mRNA","drug_class":"","quality_score":59,"revenue":"200","mechanism":"Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I."},{"drug_id":"nedosiran","indication_name":"primary hyperoxaluria type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivfloza","generic_name":"NEDOSIRAN","company_name":"Novo","drug_phase":"marketed","molecular_target":"LDHA mRNA","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production."},{"drug_id":"nedosiran","indication_name":"primary hyperoxaluria type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivfloza","generic_name":"NEDOSIRAN","company_name":"Novo","drug_phase":"marketed","molecular_target":"LDHA mRNA","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production."},{"drug_id":"succinimide","indication_name":"Primary hyperoxaluria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"succinimide","company_name":"","drug_phase":"unknown","molecular_target":"Protein cereblon, Cereblon isoform 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05843851","title":"Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria","phase":"NA","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Cystinose Stiftung","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT04982393","title":"BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":207,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04909723","title":"Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":153,"lead_sponsor_name":"Novome Biotechnologies Inc","has_results":false},{"nct_id":"NCT04756024","title":"Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT03456830","title":"Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT03067142","title":"Proteomics of Primary Hyperoxaluria Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Ann & Robert H Lurie Children's Hospital of Chicago","has_results":false},{"nct_id":"NCT03847090","title":"Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT05124886","title":"Gut Kidney Axis in Enteric Hyperoxaluria","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT04629170","title":"Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Synlogic","has_results":false},{"nct_id":"NCT04042402","title":"Long Term Extension Study in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT04571359","title":"Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT02706886","title":"Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT06578754","title":"Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing the Relationship Between Oxalate Levels and Vitamin C Levels in Plasma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Western Galilee Hospital-Nahariya","has_results":false},{"nct_id":"NCT05650112","title":"Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Federation Bio Inc.","has_results":false},{"nct_id":"NCT04119765","title":"Plasma Oxalate in Patient With Short Bowel","phase":"","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03392896","title":"Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT02795325","title":"A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT03681184","title":"A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03346369","title":"Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT03847909","title":"A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT05443932","title":"Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT04580420","title":"Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT05001269","title":"Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":true},{"nct_id":"NCT03116685","title":"A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"OxThera","has_results":true},{"nct_id":"NCT03938272","title":"An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"OxThera","has_results":true},{"nct_id":"NCT06511349","title":"Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04152200","title":"A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03350451","title":"An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT06481150","title":"A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03905694","title":"A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03391804","title":"Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT03819647","title":"Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Biocodex","has_results":false},{"nct_id":"NCT02000219","title":"Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"OxThera","has_results":true},{"nct_id":"NCT05377112","title":"Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Synlogic","has_results":false},{"nct_id":"NCT04542590","title":"Natural History of Patients With PH3 and a History of Stone Events","phase":"","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT04555486","title":"Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT06138327","title":"A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT04125472","title":"Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT05993416","title":"Treatment of Primary Hyperoxaluria Type 1 With Nedosiran","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}